Form 4: Seres Therapeutics Director Stephen Berenson Acquires Stock Options
SEC Form 4 Filing
Director Stephen Berenson acquired stock options in Seres Therapeutics, Inc. on April 4, 2024.
Summary
- Stephen Berenson, a director of Seres Therapeutics, Inc., filed a Form 4 on April 8, 2024, reporting a transaction.
- On April 4, 2024, Berenson acquired stock options to purchase 60,000 shares of Seres Therapeutics common stock at an exercise price of $0.76.
- The options vest fully on the earlier of April 4, 2025, or the day before the company's 2025 annual meeting of shareholders.
- Following the transaction, Berenson directly owns 60,000 derivative securities.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing, so the sentiment is neutral.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company directors.
Key Dates
| Date | Description |
|---|---|
| 04/04/2024 | Date of transaction: Stephen Berenson acquired stock options. |
| 04/04/2025 | Vesting date of the stock options, or the day immediately prior to the company's 2025 annual meeting of shareholders, whichever is earlier. |
| 04/03/2034 | Expiration date of the stock options. |
| 04/08/2024 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.